Dr. Yanagiya from our Business Development team will deliver an oral presentation at the event, which will be held from July 8^th (Tue) to 10^th (Thu), 2025, at TOHKnet Hall Sendai. We encourage all conference participants to attend the session.

【Event details】
Official website: The RNA Society of Japan – 年会サイト：ホーム
Date: July 8^th (Tue) -10^th (Thu), 2025: 15:00~16:12
Session8：RNA engineering and Technologies II
Venue: TOHKnet Hall Sendai (Sendai Civic Auditorium)
Access: トークネットホール仙台（仙台市民会館）

【Presentation title】
Strategies to develop efficient and safe mRNA-based therapeutics

【Abstract】
mRNA-based therapeutics are emerging as a promising resolution for vaccines, immunotherapies, and protein replacement therapies because of rapid sequence design, efficient protein expression, and relatively succinct production. ARCALIS, Inc., as a CDMO, offers end-to-end mRNA services from mRNA design to large-scale manufacturing. In collaboration with Axcelead Drug Discovery Partners, Inc., we also support in vivo testing for IND applications. Commercial production of our COVID-19 saRNA vaccine, KOSTAIVE®, has begun at our facility.

This presentation introduces three proprietary technologies:

1. A novel saRNA design platform
2. HARNA™ — a codon optimization method using machine learning
3. A nuclease P1-based method to evaluate mRNA capping efficiency

These technologies resulted in prolonged EPO protein expression in mice, improved the stability of EPO mRNA, and detection of uncapped mRNA undetectable by a conventional RNase H method—enhancing the safety and efficiency of mRNA therapeutics.